Technical Insights on Research Services Stocks -- CareDx, INC Research, Myriad Genetics, and QIAGEN

Wednesday, November 22, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 22, 2017 /PRNewswire/ -- If you want a Stock Review on CDNA, INCR, MYGN, or QGEN then come over to

and sign up for your free customized report. On Tuesday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 1.06%; the Dow Jones Industrial Average edged 0.69% higher; and the S&P 500 was up 0.65%. US
markets made broad based gains with all sectors finishing the day in green. Pre-market today, reviews these four Research Services stocks: CareDx Inc (NASDAQ: CDNA), INC Research Holdings Inc. (NASDAQ: INCR), Myriad Genetics Inc. (NASDAQ: MYGN), and QIAGEN N.V. (NASDAQ: QGEN). Access's free research reports for this morning's stocks line-up at:


Brisbane, California headquartered CareDx Inc's stock finished Tuesday's session 5.01% higher at $6.50. A total volume of 510,773 shares was traded. The Company's shares have advanced 15.66% in the past month, 202.33% over the previous three months, 116.67% in the last twelve months, and 140.74% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 31.26% and 170.86%, respectively. Furthermore, shares of CareDx, which together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, Middle-East, Africa, and Latin America, have a Relative Strength Index (RSI) of 74.94. Free research report on CDNA is available at:

INC Research Holdings

Shares in Raleigh, North Carolina headquartered INC Research Holdings Inc. ended at $37.30, up 0.27% from the last trading session. The stock recorded a trading volume of 1.29 million shares, which was above its three months average volume of 1.01 million shares. The stock is trading below its 50-day moving average by 28.45%. Moreover, shares of INC Research, which provides various clinical development services for the biopharmaceutical and medical device industries in North America, Europe, Middle-East and Africa, Asia/Pacific, and Latin America, have an RSI of 27.11. The complimentary research report on INCR can be downloaded at:

Myriad Genetics

Salt Lake City, Utah headquartered Myriad Genetics Inc.'s stock ended yesterday's session 1.04% higher at $33.00 with a total trading volume of 426,190 shares. The Company's shares have advanced 12.82% over the previous three months, 92.31% in the last twelve months, and 97.96% on an YTD basis. The stock is trading above its 200-day moving average by 30.38%. Additionally, shares of Myriad Genetics, which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide, have an RSI of 51.85. Visit us today and access our complete research report on MYGN at:


On Tuesday, shares in Venlo, the Netherlands headquartered QIAGEN N.V. recorded a trading volume of 1.89 million shares, which was above their three months average volume of 1.35 million shares. The stock finished the day 2.59% higher at $32.12. The Company's shares have advanced 15.48% over the last twelve months and 14.94% since the start of this year. The stock is trading above its 200-day moving average by 1.16%. Furthermore, shares of QIAGEN, which provides sample to insight solutions that transform biological materials into molecular insights worldwide, have an RSI of 48.54. Get free access to your research report on QGEN at:

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

View original content:


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store